Ribavirin Enhances the Action of Interferon-α against Hepatitis C Virus by Promoting the p53 Activity through the ERK1/2 Pathway

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Liu, Wei Liang ^a   Yang, Hung Chih ^b   Su, Wen Cheng ^a   Wang, Chih Chiang ^a   Chen, Hui Ling ^a   Wang, Hurng Yi ^a   Huang, Wen Hung ^a   Chen, Ding Shinn ^a   Lai, Ming Yang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; RIBAVIRIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CYCLE G1 PHASE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOLECULAR MECHANICS; PROTEIN FUNCTION; PROTEIN STABILITY; REPLICON; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL CYCLE; CELL SURVIVAL; DRUG SYNERGISM; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; REPLICON; RIBAVIRIN; RNA, VIRAL; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84866050001     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043824     Document Type: Article

References (44)

1. Graci JD, Cameron CE, (2006) Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 16: 37-48.
2. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, et al. (2004) Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126: 703-714.
3. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, et al. (1997) Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 26: 473-477.
4. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR, (2003) The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310: 333-342.
5. Reyes GR, (2001) Ribavirin: recent insights into antiviral mechanisms of action. Curr Opin Drug Dev 4: 651-656.
6. Malinoski F, Stollar V, (1981) Inhibitors of IMP dehydrogenases prevent sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology 110: 281-291.
7. Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, et al. (1998) Ribavirin inhibit viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves TH1 cytokine production but inhibits TH2 cytokine response. J Immunology 160: 3487-3493.
8. Tam RC, Pai B, Bard J, Lim C, Averett DR, et al. (1999) Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatology 30: 376-382.
9. Lau JY, Tam RC, Liang TJ, Hong Z, (2002) Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35: 1002-1009.
10. Maag D, Castro C, Hong Z, Cameron CE, (2001) Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 276: 46094-46098.
11. Lutchman G, Danehower S, Song BC, Liang TJ, Hoofnagle JA, et al. (2007) Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 132: 1757-1766.
12. Vo NV, Young KC, Lai MM, (2003) Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 42: 10462-10471.
13. Gravi JD, Cameron CE, (2002) Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology 298: 175-180.
14. Lanford RE, Chavez D, Guerra B, et al. (2001) Ribavirin induces error prone replication of GBV-B in primary tamarin hepatocytes. J Viorol 75: 8074-8081.
15. Crotty S, Cameron CE, Andino R, (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 98: 6895-6900.
16. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, et al. (2011) Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 53: 32-41.
17. Stevenson NJ, Murphy AG, Bourk NM, Keogh CA, Hegarty JE, et al. (2011) Ribavirin enhances INF-α signaling and MxA expression: A novel immune modulation mechanism during treatment of HCV. PLoS One 6: e27866.
18. Bargonetti J, Manfredi JJ, (2002) Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14: 86-91.
19. Vousden KH, Lu X, (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604.
20. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, et al. (1995) p53 dependent and independent expression of p21 during cell growth, differentiation and DNA damage. Gene Dev 9: 935-944.
21. Kubbutat MH, Jones SN, Vousden KH, (1997) Regulation of p53 stability by mdm2. Nature 387: 299-303.
22. Brooks CL, Gu W, (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15: 164-171.
23. Shieh SY, Ikeda M, Taya Y, Prives C, (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
24. Bode AM, Dong Z, (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805.
25. Persons DL, Yazlovitskaya EM, Pelling JC, (2000) Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 275: 35778-35785.
26. Yalowitz JA, Jayaram HN, (2000) Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis. Anticancer Res 20: 2329-2338.
27. Takaoka A, Hayakawa S, Yanal H, Stoiber D, Neqishi H, et al. (2003) Integration of interferon-α/β signaling to p53 responses in tumor suppression and antiviral defense. Nature 424: 516-523.
28. Dharel N, Kato N, Muroyama R, Taniquchi H, Otsuka M, et al. (2008) Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus. Hepatology 47: 1136-1149.
29. Munoz-Fontela C, Macip S, Martinez-Sobrido L, Brown L, Ashour J, et al. (2008) Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med 205: 1929-1938.
30. Su WC, Liu WL, Cheng CW, Chou YB, Hung KH, et al. (2009) Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. FEBS Lett 583: 2793-2798.
31. Zhang Y, Jamaluddin M, Wang S, Tian B, Garofalo RP, et al. (2003) Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial Cells. J Virol 77: 5933-5947.
32. Liu WL, Su WC, Cheng CW, Hwang LH, Wang CC, et al. (2006) Ribavirin up-regulates the activity of double-stranded RNA -activated protein kinase and enhances the action of interferon-α against hepatitis C virus. J Infect Diseases 196: 425-434.
33. Sen GC, Ransohoff RM, (1993) Interferon-induced antiviral actions and their regulation. Adv Virus Res 42: 57-102.
34. Wang C, Pflugheber J, Sumpter R Jr, Sodora DL, Hui D, et al. (2003) Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 77: 3898-3912.
35. Haupt Y, Maya R, Kazaz A, Oren M, (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
36. Prives C, (1998) Signaling to p53: breaking the MDM2-p53 circuit. Cell 95: 5-8.
37. Meek DW, Anderson CW, (2009) Posttranslation modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol 1: a000950.
38. Mendoza MC, Er EE, Blenis J, (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36: 320-328.
39. Pawlotsky JM, (2011) Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 3: 1742-1751.
40. Corouge M, Pol S, (2011) New treatments for chronic hepatitis C virus infection. Med Mal Infect 41: 579-587.
41. Soriano V, Vispo E, Poveda E, Labarga P, Martin-Carbonero L, et al. (2011) Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 66: 1673-1686.
42. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for he Study of Liver Diseases. Hepatology 54: 1433-1443.
43. Date T, Kato T, Miyamoto M, Zhao Z, Yasui K, et al. (2004) Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J Biol Chem 279: 22371-22376.
44. Chen SS, Chang PC, Cheng YW, Tang FM, Lin YS, (2002) Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J 21: 4491-4499.